ANTX AN2 Therapeutics, Inc. Stock Quote

ANTX [NASD]

Index	-	P/E	-	EPS (ttm)	-12.50	Insider Own	0.70%	Shs Outstand	19.40M	Perf Week	-0.95%
Market Cap	153.15M	Forward P/E	-	EPS next Y	-2.65	Insider Trans	172.84%	Shs Float	5.54M	Perf Month	-46.11%
Income	-	PEG	-	EPS next Q	-0.49	Inst Own	46.10%	Short Float	0.72%	Perf Quarter	-47.37%
Sales	-	P/S	-	EPS this Y	-92.40%	Inst Trans	-	Short Ratio	0.58	Perf Half Y	-
Book/sh	36.28	P/B	0.23	EPS next Y	-17.30%	ROA	-	Target Price	24.67	Perf Year	-
Cash/sh	6.42	P/C	1.29	EPS next 5Y	-	ROE	-	52W Range	6.88 - 23.58	Perf YTD	-46.04%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-64.76%	Beta	-
Dividend %	-	Quick Ratio	23.50	Sales past 5Y	-	Gross Margin	-	52W Low	20.80%	ATR	1.66
Employees	22	Current Ratio	23.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	39.35	Volatility	15.39% 18.59%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.75	Prev Close	8.16
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	68.54K	Price	8.31
Recom	1.50	SMA20	-11.52%	SMA50	-34.93%	SMA200	-37.55%	Volume	53,219	Change	1.84%

Jul-01-22 10:39AM	Bay Area's stream of new public companies has slowed to a weak trickle American City Business Journals +5.29%
Jun-29-22 07:00AM	AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease GlobeNewswire
Jun-27-22 09:19AM	We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate Simply Wall St.
May-10-22 04:10PM	AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates GlobeNewswire +6.88%
May-09-22 07:00AM	AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors Business Wire -19.66%
Apr-18-22 09:30AM	Here are the Bay Area's biggest startup exits of the first quarter American City Business Journals +5.49%
Mar-28-22 10:33AM	Only 9 Bay Area companies went public in this quarter. Here's how they did. American City Business Journals
Mar-25-22 04:40PM	AN2 Therapeutics Rises in First Day of Trading Barrons.com
03:06PM	RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15 Benzinga
Mar-24-22 10:32PM	AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering GlobeNewswire
02:11PM	AN2 Therapeutics Will Trade Friday. Now There Are 2 March IPOs. Barrons.com

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Jun 21	Buy	7.99	302	2,413	3,748,389	Jun 23 04:31 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Jun 14	Buy	7.97	61,424	489,402	3,748,087	Jun 15 04:25 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Jun 13	Buy	7.90	20,000	158,000	3,686,663	Jun 15 04:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience